Increased RhoA/ROK mRNA Expression and Function in Diabetic Vein Grafts Compared with Nondiabetic Vein Grafts and Diabetic Arterial Grafts

Abstract

Objective: Aim of the study was to discuss a new mechanism underlying the poor graft patency of GSV from diabetic patients and provide a rationale for selecting suitable grafts in diabetic patients. Materials and Methods: The discarded matched RA, IMA, and GSV from 7 diabetics and 7 nondiabetic patients undergoing CABG were collected and tested for their contractile response to phenylephrine (PE) and their relaxation response to fasudil (a inhibitor of Rho-kinase) and used for immunohistochemical and mRNA detection of RhoA/ROK. Results: The relaxation response to fasudil of GSV taken from diabetic patients was markedly increased but the relaxation response to fasudil of IMA and RA from diabetic patients was not. Immunohistochemistry and mRNA expression of RhoA/ROK was significantly increased in GSV from diabetic patients compared to that of IMA and RA from diabetic patients. RhoA/ROK immunohistochemistry and mRNA expression were significantly increased in GSV from diabetic patients compared with GSV from nondiabetic controls. Conclusions: RhoA/ROK expression and function in GSV from diabetic patients is significantly increased compared with IMA and RA from diabetic patients and GSV from nondiabetic patients. This contributes to a higher incidence of atherosclerosis and a lower long-term patency of GSV from diabetic patients.

Key words

coronary bypass surgery - heart disease - myocardial infarction

Reference

• 1 Kandabashi T, Shimokawa H, Mukai Y, Matoba T, Kunihiro I, Morikawa K, Ito M, Takahashi S, Kaibuchi K, Takeshita A. Involvement of Rho-kinase agonists-induced contraction of arteriosclerotic human arteries.  Arterioscler Thromb Vasc Riol. 2002;  22 243-248
• 2 Crowley C M, Lee C H, Gin S A, Keep A M, Cook R C, Breemen C V. The mechanism of excitation-contraction coupling in phenylephrine-stimulated human saphenous vein.  Am J Physiol Heart Circ Physiol. 2002;  283 H1271-H1281
• 3 Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao J K. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase.  Circulation. 2002;  106 57-62
• 4 Laufs U, Marra D, Node K, Liao J K. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p 27(KiP1).  J Biol Chem. 1999;  274 21926-21931
• 5 Seasholtz T M, Zhang T, Morissette M R, Howes A L, Yang A H, Brown J H. Increased expression and activity of RhoA are associated with increased DNA synthesis and reduced p 27(Kip 1) expression in the vasculature of hypertensive rats.  Circ Re. 2001;  89 488-495
• 6 Chaulet H, Desgranges C, Renault M A, Dupuch F, Ezan G, Peiretti F, Loirand G, Pacaud P, Gadeau A P. Extracellular nucleotides induce arterial smooth muscle cell migration via osteopontin.  Circ Res. 2001;  89 904-914
• 7 Mack C P, Somlyo A V, Hautmann M, Somlyo A P, Owens G K. Smooth muscle differentiation marker gene expression is regulated by RhoA-mediated actin polymerization.  J Biol Chem. 2001;  276 341-347
• 8 Laufs U, La Fata V, Plutzky J, Liao J K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.  Circulation. 1998;  97 1129-1135
• 9 Miao L, Calvert J W, Tang J, Parent A D, Zhang J H. Upregulation of small GTPase RhoA in the basilar artery from diabetic (mellitus) rats.  Life Sci. 2002;  71 1175-1185
• 10 Hattori T, Shimokawa H, Higashi M, Hiroki J, Mukai Y, Kaibuchi K, Takeshita A. Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice.  Circ Res. 2004;  94 46-52
• 11 Gaudino M, Luciani N, Nasso G, Salica A, Canosa C, Possati G. Is postoperative calcium channel blocker therapy needed in patients with radial artery grafts?.  J Thorac Cardiovasc Surg. 2005;  129 532-535
• 12 Shapira O M, Xu A, Vita J A, Aldea G S, Shah N, Shemin R J, Keaney Jr J F. Nitroglycerin is superior to diltizaem as a coronary bypass conduit vasodilator.  J Thorac Cardiovasc Surg. 1999;  117 906-911
• 13 Hisaoka T, Yano M, Ohkusa T, Suetsugu M, Ono K, Kohno M, Yamada J, Kobayashi S, Kohno M, Matsuzaki M. Enhancement of Rho/Rho kinase system in regulation of vascular smooth muscle contraction in tachycardial induced heart failure.  Cardiovascular Res. 2001;  49 319-329
• 15 Didion S P, Lynch C M, Baumbach G L, Faraci F M. Impaired endothelium-dependent responses and enhanced influence of Rho-kinase in cerebral arterioles in type II diabetes.  Stroke. 2005;  36 342-347
• 16 Lorusso R, Pentiricci S, Raddino R, Scarabelli T M, Zambelli C, Villanacci V, Burattin A, Romanelli G, Casari S, Scelsi R, Giustina A. Influence of type 2 diabetes on functional and structure properties of coronary artery bypass conduits.  Diabetes. 2003;  52 2814-2820
• 17 Gohla A, Schultz G, Offermanns S. Role for G12/G13 in agonist-induced vascular smooth muscle cell contraction.  Circ Res. 2000;  87 221-227
• 18 Sauzeau V, le Jeune H, Cario-Toumaniantz C, Smolenski A, Lohmann S M, Bertoglio J et al. Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle.  J Biol Chem. 2000;  275 21722-21729
• 19 Gudi T, Chen J C, Casteel D E, Seasholtz T M, Boss G R, Pilz R B. CGMP-dependent protein kinase inhibitors serum-response element-dependent transcription by inhibiting Rho activation and function.  J Biol Chem. 2002;  277 37382-37393
• 20 Akiyama N, Naruse K, Kobayashi Y, Nakamura N, Hamada Y, Nakashima E, Matsubara T, Oiso Y, Nakamura J. High glucose-induced upregulation of Rho/Rho-kinase via platelet-derived growth factor receptor-beta increases migration of aortic smooth muscle cells.  J Mol Cell Cardiol. 2008;  45 (2) 326-332
• 21 Shibuya M, Suzuki Y, Sugita K, Saito I, Sasaki T, Takakura K, Nagata I, Kikuchi H, Takemae T, Hidaka H. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial.  J Neurosurg. 1992;  76 571-577
• 22 Shimokawa H, Hiramori K, Iinuma H, Hosoda S, Kishida H, Osada H, Katagiri T, Yamauchi K, Yui Y, Minamino T, Nakashima M, Kato K. Antianginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study.  J Cardiovasc Pharmacol. 2002;  39 319-327
• 23 Gaudino M, Luciani N, Nasso G, Salica A, Canosa C, Possati G. Is postoperative calcium channel blocker therapy needed in patients with radial artery grafts?.  J Thorac Cardiovasc Surg. 2005;  129 532-535
• 24 Vicari R M, Smith W B, Chaitman B, Chrysant S G, Tonkon M J, Bitter N, Weiss R J, Thadani U. A randomized, double-blind, placebo-controlled, phase 2 study: the efficacy of fasudil in patients with stable angina.  Eur Heart J. 2004;  25 138
• 25 Arita R, Hata Y, Nakao S, Kita T, Miura M, Kawahara S, Zandi S, Almulki L, Tayyari F, Shimokawa H, Hafezi-Moghadam A, Ishibashi T. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage.  Diabetes. 2009;  58 (1) 215-226